Expert answers to your questions

Whether curating our Life Sciences content using their extensive scientific expertise, or consulting as part of our services teams, our experts are on hand to answer your questions. Including scientists and researchers, marketing and brand experts and pharmaceutical librarians, they can support research projects and answer your questions across our Life Sciences products:

R&D/Science

From the perspective of a scientist, Integrity offers access across multiple disciplines to support successful drug research and development. Updated daily by our experts, its expertly refined drug information is integrated in a single, flexible resource that can help to drive innovation and support earlier decision-making.

Commercialization

From drug discovery data to patent reports, Cortellis Competitive Intelligence can give you the confidence to make the best business decisions, faster. All content contained within Cortellis Competitive Intelligence is subject to an exhaustive editorial review, including quality approval and fact validation, with dynamic updates to content records. This ensures the most accurate and up-to-date competitive intelligence insights.

Regulatory

From the latest global regulatory documentation changes to submission guides, Cortellis Regulatory Intelligence, powered by IDRAC®, our best-in-class regulatory content is an innovative new way to access and use Thomson Reuters regulatory information faster and more intuitively.

Generics

For demanding professionals in generic pharmaceutical companies, OTC and API manufacturers, we can help identify and evaluate new product development and licensing opportunities ahead of the competition for both small molecules and follow-on biologics, with the Newport product suite.

 

Meet our Experts

As a Thomson Reuters Life Sciences customer you get on-demand research support from our scientific experts

R&D

Clara Verges

Clara Verges

Manager, Biologicals Content
 

More information about Clara Verges

 

 

Susanna Rique

Susanna Rique

Genomics and Biomarkers
 

More information about Susanna Rique

 

Jerome Breton

JÉRÔME BRETON

Manager, Chemistry and Chemical Data
 

More information about Jérôme Breton

 

 

Beth Nuskey

Beth Nuskey

Clinical Trials Content Expert
 

More information about Beth Nuskey

 

Commercialization

Elsa Arias

Elsa Arias

Clinical Trials
 

More information about Elsa Arias

 

 

Gez Cross

Gez Cross

Manager, Patent Current Awareness
 

More information about Gez Cross

 

 

Alexandra Kibble

Alexandra Kibble

Drug Forecast and Marketing data
 

More information about Alexandra Kibble

 

Shujuan Liu

Shujuan Liu

Chinese Pharmaceuticals and Healthcare
 

More information about Shujuan Liu

 

 

Peter Robins

Peter Robins

Manager, Drug Pipeline
 

More information about Peter Robins

 

 

Maki Watanabe

Maki Watanabe

Japanese Pharmaceuticals and Healthcare
 

More information about Maki Watanabe

 

Regulatory

Akiko Hihara

Akiko Hihara

Managing Editor
Asia

More information about Akiko Hihara

 

 

Anne Lecocq

Anne Lecocq

Senior Manager
Europe

More information about Anne Lecocq

 

 

Joaquín Fernández

Joaquín Fernández

Managing Editor
Europe

More information about Joaquín Fernández

 

 

Monia Tumminello

Monia Tumminello

Managing Editor
Regulatory Intelligence

More information about Monia Tumminello

 

 

Marta Guinart

Marta Guinart

Managing Editor
Regulatory Intelligence

More information about Marta Guinart

 

 

Samirah  Hamaui

Samirah Hamaui Cuardrado

Managing Editor
Regulatory Intelligence

More information about Samirah Hamaui

 

Rosanna Melchior

Rosanna Melchior

Senior Project Manager
Canada, Asia Pacific and Middle East & Africa

More information about Rosanna Melchior

 

 

Zeineb Merimi

Zeineb Merimi

Managing Editor
Middle East & Africa, Australia and Israel

More information about Zeineb Merimi

 

 

Marie Domitille Petit

Marie Domitille Petit

Regulatory expert
Europe

More information about Marie Petit

 

 

Sergio Held

Sergio Held

Managing Editor
Regulatory Intelligence

More information about Sergio Held

 

 

Jianhui Zheng

Jianhui Zheng

Managing Editor
Canada, China, India, Indonesia, Philippines, Taiwan and Vietnam

More information about Jianhui Zheng

 

Generics

Molly Bowman

Molly Bowman

Research Manager
 

More information about Molly Bowman

 

Benjamin Burck

Benjamin Burck

Paragraph IV Patent Challenges Content Expert
 

More information about Benjamin Burck

 

TRENDING QUESTIONS

Here are just a few of the questions our editorial team has helped customers with over the past few months.

  1. Ranbaxy was recently hit with a paragraph IV filing from Watson relating to Absorica. I wanted to get your opinion on potential outcomes of this case. In the worst case scenario, how soon could Watson start producing a generic?
  2. I am interested in information and figures related to the API market in South America.
  3. Could one of your experts please send me a reliable source of information about European API manufacturers complying with GMP requirements?
  4. When a drug has received central authorization in the EU but is not commercially available yet, what is the most appropriate route of supply until commercially available in each member state?
  5. In Argentina and Colombia, could you please explain which type of documents are enforceable and which ones are just recommendations? For instance, I still don't know whether a Circular is enforceable or not.
  6. Are manufacturing site/company registrations required in Egypt, UAE and Saudi Arabia? If yes, what are the requirements?
  7. In the EU, is there a legal deadline for regulatory authorities to evaluate and issue registration of medicines and medical devices?
  8. Do you have some article related to the API market in South America or could you indicate a source of research that show all figures on this market?
  9. Please could you confirm whether GFT-505 is really still being developed in phase II for obesity?
  10. What is the success rate to market of neurological drugs once they have reached phase III trials?
  11. Is the company M's Science Corp still active?
  12. Are you able to provide patent data and sales forecast data for the drug Xtandi in Latin America?

Ask the Scientific Expert is here to support research requests that will benefit from our editorial insight and expertise. If you have any questions relating specifically to editorial content and policy, have identified errors, or wish to report technical issues, please use our Customer Technical Support helpdesk.

View Ask the Scientific Expert Terms and Conditions

Ask an Expert TODAY